Open Access

Sialyl Lewisx expression at the invasive front as a predictive marker of liver recurrence in stage II colorectal cancer

  • Authors:
    • Masato Yamadera
    • Eiji Shinto
    • Hitoshi Tsuda
    • Yoshiki Kajiwara
    • Yoshihisa Naito
    • Kazuo Hase
    • Junji Yamamoto
    • Hideki Ueno
  • View Affiliations

  • Published online on: November 3, 2017     https://doi.org/10.3892/ol.2017.7340
  • Pages:221-228
  • Copyright: © Yamadera et al. This is an open access article distributed under the terms of Creative Commons Attribution License.

Metrics: HTML 0 views | PDF 0 views
0

Abstract

Sialyl Lewisx (SLX) is a carbohydrate ligand for endothelial selectin that participates in cell adhesion, proliferation and scattering. It plays an important role in cancer cell adhesion to vascular endothelial cells, leading to hematogenous metastasis. The prognostic significance of SLX expression level at the invasive front in patients with stage II colorectal cancer (CRC) was examined. A total of 209 patients with stage II CRC curatively resected between 1997 and 2000 were enrolled. The preoperative serum SLX levels measured by radioimmunoassay and SLX immunoexpression levels at the invasive front, and at the non‑invasive frontal region determined by tissue microarray were analyzed. SLX expression at the invasive front was positively associated with tumor invasion depth (P=0.007) and tumor budding grade (P=0.038). Disease‑free survival curves differed between the high and low SLX‑expression groups (5‑year survival rates, 77.0 and 89.7%, respectively; P=0.036). Liver cancer recurrence was more frequent in the high‑expression group than in the low‑expression group (15.9 and 2.4%; P=0.002). Multivariate analysis revealed that its expression (hazard ratio, 5.26; P=0.015) and venous invasion (hazard ratio, 4.14; P=0.040) were independent predictive markers of liver cancer recurrence. Neither the preoperative serum SLX level nor SLX expression at the non‑invasive frontal region showed any association with histopathological features or disease‑free survival. SLX expression level at the invasive front is a promising marker for identifying patients with stage II CRC with a high risk of liver cancer recurrence.

Related Articles

Journal Cover

January 2018
Volume 15 Issue 1

Print ISSN: 1792-1074
Online ISSN:1792-1082

2016 Impact Factor: 1.39
Ranked #68/217 Oncology
(total number of cites)

Sign up for eToc alerts

Recommend to Library

Copy and paste a formatted citation
APA
Yamadera, M., Shinto, E., Tsuda, H., Kajiwara, Y., Naito, Y., Hase, K. ... Ueno, H. (2018). Sialyl Lewisx expression at the invasive front as a predictive marker of liver recurrence in stage II colorectal cancer. Oncology Letters, 15, 221-228. https://doi.org/10.3892/ol.2017.7340
MLA
Yamadera, M., Shinto, E., Tsuda, H., Kajiwara, Y., Naito, Y., Hase, K., Yamamoto, J., Ueno, H."Sialyl Lewisx expression at the invasive front as a predictive marker of liver recurrence in stage II colorectal cancer". Oncology Letters 15.1 (2018): 221-228.
Chicago
Yamadera, M., Shinto, E., Tsuda, H., Kajiwara, Y., Naito, Y., Hase, K., Yamamoto, J., Ueno, H."Sialyl Lewisx expression at the invasive front as a predictive marker of liver recurrence in stage II colorectal cancer". Oncology Letters 15, no. 1 (2018): 221-228. https://doi.org/10.3892/ol.2017.7340